Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EPS (Basic) (2016 - 2026)

Intellia Therapeutics has reported EPS (Basic) over the past 12 years, most recently at -$0.81 for Q1 2026.

  • Quarterly EPS (Basic) rose 26.36% to -$0.81 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.53 through Mar 2026, up 32.38% year-over-year, with the annual reading at -$3.81 for FY2025, 27.43% up from the prior year.
  • EPS (Basic) was -$0.81 for Q1 2026 at Intellia Therapeutics, up from -$0.82 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.81 in Q1 2026 and troughed at -$1.96 in Q1 2022.
  • The 5-year median for EPS (Basic) is -$1.33 (2022), against an average of -$1.26.
  • Year-over-year, EPS (Basic) tumbled 184.06% in 2022 and then skyrocketed 40.31% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$1.38 in 2022, then fell by 5.8% to -$1.46 in 2023, then grew by 13.7% to -$1.26 in 2024, then surged by 34.92% to -$0.82 in 2025, then increased by 1.22% to -$0.81 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's EPS (Basic) are -$0.81 (Q1 2026), -$0.82 (Q4 2025), and -$0.92 (Q3 2025).